Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compoun...(current standard of care and patients wi...),Health

Date:4/24/2008

current standard of care, and patients with non-alcoholic fatty liver disease (NAFLD), there are currently no therapeutic options available to prevent progression to cirrhosis, liver failure and liver cancer," stated Dr. Gane. "In the future, these patients may benefit from maintenance therapy with interventions such as MitoQ, which block either hepatic necroinflammation or fibrogenesis."

"In the coming year, Antipodean plans to explore and develop its lead compound for the treatment of hepatological diseases, particularly non- alcoholic fatty liver disease (NAFLD)," said Ken Taylor, Ph.D., Chief Executive Officer of Antipodean Pharmaceuticals. "The Company is actively seeking to achieve this goal with the help of a pharmaceutical partner."

A 12-month study in patients in Parkinson's disease showed MitoQ to be well tolerated; however, there was no significant effect on disease progression. Dr. Barry Snow, Department of Neurology, Auckland Hospital, New Zealand and Principal Investigator of the trial of MitoQ in Parkinson's disease, believes that the lack of efficacy in Parkinson's Disease may have been due to the large number of impaired cells in that disease; these cells may have had limited or no ability to regenerate, and thus could not benefit from MitoQ's antioxidant properties. The Company believes MitoQ has therapeutic potential in diseases where cell regeneration occurs, such as hepatological and dermatological disorders.

About MitoQ(R)

MitoQ(R) is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative damage and prevents liver cell apoptosis. MitoQ is based on a novel technology, targeted lipophilic cations that transport and concentrate antioxidants into the mitochondria-organelles inside cells that provide energy for life processes-where they accumulate up to a thousand fold. Targeted antioxidants can reduce the hepatic oxidative damage that is induced by viral infection and that is also involved in
'/>"/>

SOURCE Antipodean Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Jazz Pharmaceuticals to Present at Morgan Stanley Conference
2. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
3. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
4. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
5. Amylin Pharmaceuticals Reports First Quarter Financial Results
6. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
7. Access Pharmaceuticals Announces New Data on Angiolix(R)
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
11. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast